Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer

Hiroyuki Yasuda, Lorena L. De Figueiredo-Pontes, Susumu Kobayashi, Daniel B. Costa

Research output: Contribution to journalArticlepeer-review

122 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences